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Background and aims: Our previous in vitro and clinical work has demonstrated anti-inflammatory effects of berberine
(BBR), but the clinical application of BBR is limited by its poor bioavailability. Derivatives of BBR have been suggested to
have enhanced bioavailability compared to BBR. In this study, we tested whether BBR derivatives, compared with BBR,
had superior beneficial effects on atherosclerotic plaques in apoE−/− mice, and defined possible molecular mechanisms
underlying such effects.
Methods: Macrophages were pretreated with BBR and its derivatives, dihydroberberine (dhBBR) and 8,8-
dimethyldihydroberberine (Di-MeBBR), before incubation with oxLDL. Cell surface EMMPRIN expression was measured by
flow cytometry and Western blotting, and phospho-(p)-p38, p-JNK, nuclear NFκB p65, and phospho-p65 were measured
by Western blotting. ApoE−/− mice fed with the Western diet for 16 weeks were treated with BBR, dhBBR and Di-MeBBR
16 weeks. Aortic atherosclerotic lesion size, plaque matrix proteins, and EMMPRIN and other inflammatory factors were
measured using Oil Red O Staining, Masson’s trichromestaining and immunohistochemical staining and real-time PCR.
Results: Compared with BBR, dhBBR and Di-MeBBR significantly reduced EMMPRIN expression, which was associated
with a greater inhibition of p-p38, p-JNK, nuclear NFκB p65 and phospho-p65 induced by oxLDL in macrophages.
dhBBR and Di-MeBBR, but not BBR, reduced atherosclerotic plaque size and improved plaque stability indicated by
increased α-smooth muscle actin and collagen content, and thicker fibrous caps. dhBBR and Di-MeBBR reduced
expression of EMMPRIN, CD68, and NFκB p65, and Di-MeBBR also reduced expression of matrix metalloproteinase-9,
intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in aortic plaques.
Conclusions: These results have demonstrated that BBR derivatives, dhBBR and Di-MeBBR, are superior to BBR in
inhibiting inflammation and reducing plaque size and vulnerability.
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Atherosclerosis is a chronic inflammatory disease affecting
large and medium-sized arteries throughout the body
[1,2]. In the early course of the disease, monocytes adhere
to dysfunctional vascular endothelium and migrate into
the subendothelial layer of the intima where they differen-
tiate into macrophages. These macrophages transform
into foam cells when the subendothelial space is enriched
with atherogenic lipoproteins [3]. Foam cells aggregate to
form the atheromatous core of the atherosclerotic plaques.* Correspondence: msdoctor@126.com
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unless otherwise stated.Macrophages and foam cells secret a variety of inflamma-
tory factors, which attract more monocytes to infiltrate
into the subendothelial space, propagate inflammatory re-
sponse and subsequently advance atherosclerotic plaques
[4]. Macrophage and foam cells also express several matrix
metalloproteinases (MMPs), such as MMP-9 and extracel-
lular matrix metalloproteinase inducer (EMMPRIN) [5,6],
which, in turn, contribute to vulnerability of atheroscler-
otic plaques [7,8]. A plaque with a large lipid core and
covered by a thin fibrous cap is at a higher risk for rupture
[9]. The ruptured fibrous cap is known to be rich in mac-
rophages that produce MMPs, thus digesting extracellular
matrix and weakening the fibrous cap. The rupture of an
atherosclerotic plaque followed by thrombus formationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Therefore, reducing atherosclerotic plaque size and pre-
venting the rupture of vulnerable plaques are essential to
preventing emergency medical conditions. In view of the
important roles of MMP-9 and EMMPRIN in vulnerabil-
ity of atherosclerotic plaques, MMP-9 and EMMPRIN are
potential targets for therapeutic inventions to inhibit
plaque rupture and acute medical conditions.
Berberine (BBR) can be isolated from many different
medicinal herbs, such as Berberis, Phellodendron amur-
ense (Huang Po), Coptis chinensis (Huang Lian) [11].
Our previous studies demonstrated that BBR markedly
inhibited both mRNA and protein levels of EMMPRIN
and MMP-9 in phorbol myristate acetate (PMA)- in-
duced macrophages [12,13]. We further demonstrated
that BBR treatment for 30 days, as an adjunct therapy,
reduced serum levels of MMP-9, intercellular adhesion
molecule (ICAM)-1 and vascular cell adhesion molecule
(VCAM)-1 in patients with acute coronary syndrome
(ACS) following percutaneous coronary intervention
when compared with standard therapy alone [14].
However, whether BBR reduces plaque size and im-
proves plaque stability in animal models is yet to be ex-
plored. In addition, several studies have shown that BBR
derivatives, such as dihydroberberine (dhBBR) and 8, 8-
dimethyldihydroberberine (Di-MeBBR), are more bio-
logically available compared with BBR [15,16], suggesting
that BBR derivatives may have greater anti-inflammatory
and anti-atherosclerotic effects than BBR.
Therefore, the aims of this study are: 1) to evaluate the
inhibitory effects of BBR derivatives on EMMPRIN ex-
pression in macrophages and foam cells, in comparison
with BBR; 2) to explore whether BBR and its derivatives
have in vivo anti-atherosclerotic efficacy in apolipopro-
tein E knock-out (apoE−/−) mice; 3) to study signaling




Cells from a human monocytic cell line (THP-1 cells,
obtained from the American Type Culture Collection)
were cultured at a density of 106/mL in RPMI-1640
medium (Hycolone, USA) supplemented with 10% FBS,
and 100 U/mL penicillin/streptomycin solution. To induce
differentiation of monocytes into macrophages, THP-1
cells were cultured in 100 nM PMA (Calbiochem) for
48 h as previously described [17]. PMA-induced macro-
phages (2 × 106/mL) were pretreated with BBR (25 μM),
or Di-MeBBR (25 μM), dhBBR (25 μM) or thBBR (tetra-
hydroberberine, 25 μM) for 1 h prior to incubation with
oxLDL (50 μg/mL) for the indicated times for different as-
says. Then, flow cytometry analysis and Western blotting
were performed.Flow cytometry
The expression of EMMPRIN on the cell surface was deter-
mined by flow cytometry. Cells were collected, incubated
with FcR blocking reagent and stained directly with a fluor-
escein isothiocyanate (FITC)-conjugated anti-EMMPRIN
antibody (BD, USA) according to the manufacturer’s
instruction. An isotype control (BD, USA) was included in
each experiment to identify background staining. Samples
were analyzed on a BD FACSCalibur flow cytometer
(Becton Dickinson, USA).
Protein isolation and Western blotting analysis
Protein isolation and Western blotting analysis of cell ly-
sates were performed as previously described [12,13]. For
the analysis of nuclear NFκB p65, NE-PER nuclear and
cytoplasmic extraction reagents (Pierce, USA) were used
to separate cytoplasmic and nuclear fractions. Membranes
were first probed with primary antibodies for phospho-
ERK, ERK, phospho-p38, p38, phospho-JNK, JNK, NFκB
p65, phospho-p65 (Ser536), EMMPRIN, and GAPDH
(Cell Signaling Technology, USA), and lamin B (Sigma-
Aldrich, USA), and then incubated with anti-rabbit or
anti-mouse secondary antibodies (Cell Signaling Technology,
USA), followed by incubation with antibody labeled
with far-red fluorescent Alexa Fluor 680 dye. All signals
were detected by the Odyssey Infrared Imaging System
(LI-COR, USA) and data were normalized by GAPDH
or lamin B levels (for NFκB p65).
Animal experiments
All animal experiments were carried out in accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals. All methods were ap-
proved by the Ethics Committee of Shanghai Jiaotong
University School of Medicine. Male apoE−/− mice were
obtained from the Animal Research Center of Beijing
University. 12-week-old mice (n = 20 per group) were
fed with the Western diet (32% fat, 1% cholesterol;
Shanghai Slac Laboratory Animal Co. Ltd) for 16 weeks.
Mice were treated with BBR (10 mg/kg/d), Di-MeBBR
(10 mg/kg/d) or dhBBR (10 mg/kg/d) orally for 16 weeks.
BBR was purchased from Sigma-Aldrich, and Di-MeBBR
and dhBBR were synthesized by the Shanghai Institute
of Materia Medica (Figure 1A) [15]. A control group re-
ceived phosphate buffered saline (PBS) alone. Following
16 weeks of treatment, mice fasted overnight and were
subsequently euthanized for tissue harvesting. Total
cholesterol (TC), triglycerides (TG), low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) were measured from blood ob-
tained by retro-orbital bleeding. Serum lipids were deter-
mined using the Roche Automatic Analyzer modular
P800 (Roche Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions.
Figure 1 Molecular structures of berberine and its derivatives and their effects on EMMPRIN expression. (A) Molecular structures of
berberine (BBR) and its derivatives, dihydroberberine (dhBBR), and 8,8-dimethyldi-hydroberberine (di-MeBBR). (B-D) The effects of BBR and its
derivatives on EMMPRIN expression was monitored by measuring the induction of EMMPRIN via flow cytometry (B) and Western blotting (C, D).
PMA-induced macrophages were treated with BBR or its derivatives for 1 h (macrophages), or pre-treated with BBR or its derivatives for 1 h prior
to incubation with oxLDL (50 μg/mL) for 24 h (foam cells). The expression of EMMPRIN was detected by flow cytometric analysis. *P < 0.05 vs. BBR
group. #P < 0.05 vs. untreated control group. thBBR: tetrahydroberberine.
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To examine lipid and plaque accumulation in the aorta,
Oil Red O Staining was performed. Mice were perfused
through the left ventricle with isotonic saline and then4% paraformaldehyde in 0.01 M phosphate buffer
(pH 7.4). The aorta samples were collected and proc-
essed for Oil Red O staining [18]. Briefly, each aorta was
rinsed in distilled water using a syringe with needle,
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in the Oil Red O working solution (Sigma-Aldrich), and
then rinsed again for 10 s in 70% 2-propanol. After that,
the aorta was transferred to double-distilled water. This
procedure results in red staining of all regions in which
atherosclerotic lesions are present. Images were captured
by a Canon lSD780 IS digital camera (Tokyo, Japan) and
the lesion area was quantitated using Quantity One ana-
lysis system (Version 4.6.2). The lesion area of aortic
atherosclerosis was expressed as the percentage of Oil
Red O-stained area relative to the surface area of the en-
tire aorta (n = 6). All researchers conducting the data
capture and analysis were blinded to group.
Histological analysis
The aorta (from the arch to abdominal aorta) was used.
Serial 6 μm sections (40 sections per mouse) of the aorta
were collected for immunohistochemical staining and
Masson’s trichrome staining. Immunohistochemistry was
used to characterize macrophages (CD68, dilution 1:80,
Abcam, Cambridge, UK); α-smooth muscle actin (α-SMA,
dilution 1:100, Abcam); EMMPRIN (dilution 1:250, Abcam);
MMP-9 (dilution 1:300, Abcam); VCAM-1 (dilution 1:200,
Abcam); ICAM-1 (dilution 1:150, Abcam); and NFκB
p65 (dilution 1:50, Cell Signaling Technology, Inc.) as
previously described [13]. Immunohistochemical staining
was visualized using an EnVision kit (DAKO) according to
the manufacturer’s instructions. Collagen content in the
tissue was assessed by Masson’s trichrome staining, similar
to the methods previously described [19]. Images were cap-
tured with a light microscope camera system (Olympus,
Tokyo, Japan) and analyzed using Quantity One analysis
system. The results were expressed as the percentage of
stained area to total plaque area [20,21]. Fibrous cap thick-
ness of lesion area was evaluated on the most advanced le-
sion in each mouse by using α-SMA-stained slides.
Real-time PCR
Total RNA was isolated from the aorta using Trizol
(Invitrogen, USA). Real-time PCR was performed to de-









α-SMA, α-smooth muscle actin; EMMPRIN, extracellular matrix metalloproteinases in
NFκB, nuclear factor-κB; VCAM-1, vascular cell adhesion molecule-1.p65, ICAM-1, VCAM-1, and CD68. The primer sequences
are shown in Table 1. mRNA levels of target genes were
normalized to the house keeping gene GAPDH.
Statistical analysis
SPSS v17.0 statistical software package was used for data
analysis. Results were expressed as mean ± standard devi-
ation. All variables were tested for homogeneity of variance
by Levènes test. If data were distributed normally with
equal variance, multiple-comparison tests between the
groups were performed with one-way ANOVA followed by
Student-Newman-Keuls post hoc analysis. Otherwise,
multiple-comparison were analysed using nonparametric
Kruskal-Wallis one-way ANOVA followed by Bonferroni




Effects of BBR and its derivatives on EMMPRIN expression
Since EMMPRIN functions as an upstream regulator of
MMPs such as MMP-9 [22,23], we compared the effects
of BBR and its derivatives on EMMPRIN expression by
flow cytometric analysis and Western blotting. PMA-
induced macrophages were treated with BBR or its de-
rivatives for 1 h (macrophages), or pre-treated with BBR
or its derivatives for 1 h prior to incubation with oxLDL
(50 μg/mL) for 24 h (foam cells). Compared to BBR
group, Di-MeBBR and dhBBR groups showed lower
EMMPRIN expression in both macrophages and foam
cells (Figure 1b-d, P < 0.05), but thBBR group did not
differ from BBR group. So, we only tested dhBBR and
Di-MeBBR for the following investigations in this study.
Effects of BBR and its derivative on activation of MAPK
pathways
Our previous studies and other studies suggested that
mitogen-activated protein kinase (MAPK) pathways were
involved in expression of EMMPRIN, MMP-9 and CD68
and formation of foam cells [12,13,24], so we studied the









ducer; ICAM-1, intercellular adhesion molecule-1; MMP-9, metalloproteinase-9;
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were pretreated with BBR and its derivatives for 1 h, and
then stimulated with oxLDL for 10, 30 and 60 min. We
found that oxLDL increased phosphorylation of p38 and
JNK at 10, 30 and 60 min, but it had no effect on ERK1/2Figure 2 Effects of berberine and its derivatives on activation of MAP
pretreated with berberine for 1 h, and then incubated with oxLDL for 10, 3
measure protein levels of phospho (p)-p38, p-ERK1/2, and p-JNK. (A) Repre
p-ERK1/2 and p-JNK bands. (C-D)Cells were pretreated with berberine or dh
30 and 60 min. The cell lysates were collected for Western blotting to mea
blotting. (D) Quantification of p-p38, p-ERK1/2 and p-JNK bands.GAPDH ex
BBR group.phosphorylation (Figure 2A,B). BBR pretreatment de-
creased phosphorylation of p38 and JNK induced by
oxLDL (Figure 2A, B). Compared to BBR, Di-MeBBR and
dhBBR had a greater inhibition of phosphorylation of p38
and JNK (Figure 2C, D).K signaling pathways induced by oxLDL. (A-B) Cells were
0 and 60 min. The cell lysates were collected for Western blotting to
sentative bands of Western blotting. (B) Quantification of p-p38,
BBR, or Di-MeBBR for 1 h, followed by incubation with oxLDL for 10,
sure phospho (p)-p38 and p-JNK. (C) Representative bands of Western
pression was used for protein level normalization. *P < 0.05 vs.
Chen et al. Journal of Translational Medicine 2014, 12:326 Page 6 of 13
http://www.translational-medicine.com/content/12/1/326Effects of BBR and its derivative on translocation of NFκB
p65 to the nucleus
Our previous study showed that BBR also suppressed
MMP-9 and EMMPRIN expression by inhibiting NFκB
p65 activation in oxLDL-stimulated macrophages [12].
In this study, we examined whether BBR derivatives had
greater impacts on the activation of NFκB p65. Macro-
phage were pretreated with BBR, Di-MeBBR and dhBBR,
and then stimulated with oxLDL for 1, 3 and 6 h. NFκB
p65 and phosho-p65 in nuclear fractions of macrophages
were significantly increased by stimulation with oxLDL
for 1, 3, and 6 h (Figure 3A, C). p65 peaked at 3 h and
phosphor-p65 peaked at 1 and 3 h. Compared to BBR,
Di-MeBBR and dhBBR blocked the nuclear transloca-
tion of NFκB p65 and phosho-p65 more significantly
(Figure 3B, D, E).
In vivo studies
Body weight and serum lipids
At the time of sacrifice, there was no difference in body
weight between the experimental and control mice
(P >0.05). Compared with the control group, TC levels
were significantly lower in Di-MeBBR and BBR group.
LDL-C levels were significantly lower in BBR, dhBBR
and Di-MeBBR group (Table 2). TG and HDL-C levels
did not differ among groups.
Aortic atherosclerotic lesion area
The lesion area was significantly smaller in mice treated
with dhBBR and Di-MeBBR compared with control mice
(P < 0.05). There was no difference in lesion area be-
tween BBR group and the control group (Figure 4A, B).Figure 3 Comparisons of berberine and its derivatives on activation of
dhBBR, or Di-MeBBR for 1 h, followed by incubation with oxLDL for 1, 3, and 6
were measured by Western blotting. (A, C) Effects of oxLDL on nuclear transl
and its derivatives (dhBBR, di-MeBBR) on nuclear translocation of NFκB p65 an
level normalization. *P < 0.05 vs. BBR group. #P < 0.05 vs. 0 h (C) or untreatedExpression of CD68, EMMPRIN, MMP-9, NFκB, ICAM-1 and
VCAM-1
As macrophage accumulation in the arterial wall contributes
to atherosclerotic lesion development, we investigated ex-
pression of the macrophage marker, CD68, by immunohis-
tochemistry in atherosclerotic plaques (Figures 5 and 6) and
real-time PCR in the aorta (Figure 7). We also measured
EMMPRIN, MMP-9, NFκB p65, and two key cell adhesion
molecules (ICAM-1, VCAM-1) by immunohistochemistry
(Figures 5 and 6) and real-time PCR (Figure 7). Compared to
vehicle control, Di-MeBBR significantly reduced expression
of CD68, EMMPRIN, NFκB p65, MMP-9, ICAM-1 and
VCAM-1, whereas dhBBR significantly reduced expression
of CD68, EMMPRIN, and NFκB p65, without signifi-
cant effect on expression of MMP-9, ICAM-1 and
VCAM-1. BBR did not have effect on the expression of
any of these molecules (Figures 5, 6 and 7).
α-SMA and collagen in atherosclerotic plaques
We further determined α-SMA and collagen levels in
plaques using immunohistochemistry and Masson’s tri-
chrome staining, respectively. Compared to vehicle
control group, Di-MeBBR group had more collagen de-
position (Figure 8B), while dhBBR group showed in-
creases in α-SMA content (Figure 8A) and fibrous cap
thickness (Figure 8C). However, BBR had no effect on
collagen, α-SMA and fibrous cap thickness.
Discussion
Our previous studies have found that BBR inhibits MMP-
9 and EMMPRIN expression in macrophages [12] and
also decreases plasma MMP-9, ICAM-1 and VCAM-1 inMAPK signaling pathways. Cells were pretreated with berberine or
h. Nuclear fractions were isolated, nuclear NFκB p65 and phospho-p65
ocation of NFκB p65 and phospho-p65 expression. (B, D, D) Berberine
d phospho-p65 expression. Lamin B and β-Actin was used for protein
control group (D, E).
Table 2 The effects of BBR and its derivatives on weight and lipid profiles
Weight (g) TG (mmol/L) TC (mmol/L) HDL-C (mmol/L) LDL-C (mmol/L)
Control 34.2 ± 0.5 5 ± 1.1 22.9 ± 1.5 1.6 ± 0.25 5.9 ± 1.12
BBR 33.4 ± 0.7 3.9 ± 0.8 17.3 ± 2.1* 1.7 ± 0.31 4.8 ± 1.2*
dhBBR 32.1 ± 1.2 4.2 ± 0.7 21.6 ± 1.8 1.6 ± 0.29 5.1 ± 1.3*
Di-MeBBR 33.6 ± 1.7 4.4 ± 0.9 18.9 ± 1.3* 1.8 ± 0.32 4.5 ± 0.9*
Data are shown as means ± SD. *P <0.05 vs. control. TG, total triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; BBR, berberine; dhBBR, dihdroberberine; Di-MeBBR, 8,8-dimethyldihydroberberine.
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is limited by its poor bioavailability. In the present study,
we evaluate anti-atherosclerotic effects of BBR derivatives
(known to have enhanced bioavailability) in vitro and
in vivo, in comparison with BBR. Our in vitro study
showed that BBR and its derivatives, dhBBR and Di-
MeBBR, decreased EMMPRIN expression and inhibited
phosphorylation of p38 and JNK and nuclear translocation
of NFκB p65 induced by oxLDL in macrophages, with
dhBBR and Di-MeBBR showing greater effects in com-
parison with BBR. Our in vivo study demonstrated that
dhBBR and Di-MeBBR reduced aortic atherosclerotic le-
sion size, improved plaque stability (increased α-SMA and
collagen content, and increased fibrous cap thickness),
and decreased EMMPRIN, MMP-9, CD68, ICAM-1,
VCAM-1 and NFκB p65 expression when compared with
vehicle control in apoE−/− mice fed with the Western
diet. However, BBR at the same dosage did not show
beneficial effect on atherosclerosis in apoE−/− mice. Take
together, our results have shown that dhBBR and Di-
MeBBR have better anti-inflammatory effects than BBR, and
dhBBR and Di-MeBBR, but not BBR, reduce atherosclerotic
plaque size and improve plaque stability in apoE−/− mice.
Therefore, dhBBR and Di-MeBBR have therapeutic advan-
tages over BBR as an attractive adjunct therapy in patients
with atherosclerosis.Figure 4 Effects of berberine and its derivatives on atherosclerotic plaq
and then treated with BBR (b) or its derivatives, Di-MeBBR (c) and dhBBR (d) fo
atherosclerotic lesions were stained by Oil RedO. (B) Plaque area was quantifie
*P < 0.05 vs. the control group.Although our previous in vitro and clinical studies
have shown that BBR has anti-inflammatory effects, we
have not explored whether BBR reduces atherosclerosis
in animal models. In the present study, we have demon-
strated that BBR derivatives at 10 mg/kg/d not only re-
duce plaque size, but also improve plaque stability in
apoE−/− mice, however BBR at the same dosage had no
significant anti-atherosclerotic effect. One of the earliest
events in atherogenesis is the adhesion of monocytes to
the vascular endothelium, which is mainly mediated by
ICAM-1 and VCAM-1 [25]. Following initial adhesion,
monocytes subsequently infiltrate into the subendothe-
lial space and differentiate into macrophages. Macro-
phages and foam cells contribute to the initiation and
development of atherosclerosis by forming fatty streak
and secreting a variety of inflammatory mediators [4]. In
this study, we found that both dhBBR and Di-MeBBR re-
duced CD68 expression in atherosclerotic plaques in
apoE−/− mice, indicating reduced infiltration of macro-
phages. Di-MeBBR also decreased ICAM-1 and VCAM-
1 expression in atherosclerotic plaques, thus inhibiting
the initial step of monocyte recruitment. Although our
previous clinical research showed BBR reduced plasma
ICAM-1 and VCAM-1 in patients with ACS [14], BBR
had no effect on CD68, ICAM-1 and VCAM-1 in
apoE−/− mice. Macrophages also contribute to plaqueue area. ApoE−/− mice were fed with the Western diet for 16 weeks
r 16 weeks. Mice receiving PBS served as the control group (a). (A) The
d as the percentage of Oil Red O-stained area to total aortic surface area.
Figure 5 Effects of berberine and its derivatives on CD68, EMMPRIN, and NFκB p65 protein expression in atherosclerotic plaques.
ApoE−/− mice were fed with the Western diet for 16 weeks and then treated with BBR (b) or its derivatives, Di-MeBBR (c) and dhBBR (d) for 16
weeks. Mice receiving PBS served as the control group (a). Mouse aorta sections were collected. Representative immunostaining images and
quantification of CD68 (A), EMMPRIN (B) and NFκB p65 (C) in atherosclerotic plaques. Scale bar represents 100 μm. *P < 0.05 vs. the control group.
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matrix proteins and weaken the fibrous cap [26,27].
Among various MMP species, MMP-9, mainly derivingfrom macrophages and foam cells, plays an important
role in plaque rupture and ACS [7,27,28]. EMMPRIN is
an upstream inducer of MMPs [6,22,23], and it induces
Figure 6 Effects of berberine and its derivatives on protein expression of inflammatory mediators in atherosclerotic plaques.
ApoE−/− mice were fed with the Western diet for 16 weeks and then treated with BBR (b) or its derivatives, Di-MeBBR (c) and dhBBR (d) for 16
weeks. Mice receiving PBS served as the control group (a). Mouse aorta sections were collected. Representative immunostaining images and
quantification of MMP-9 (A), ICAM-1 (B) and VCAM-1 (C) in atherosclerotic plaques. Scale bar represents 100 μm. *P < 0.05 vs. the control group.
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[29]. We previously found that BBR inhibited MMP-9
and EMMRIN expression in macrophages. In thisstudy, we further showed that dhBBR and Di-MeBBR,
compared with BBR, had greater inhibitory effects on
EMMPRIN expression in both macrophages stimulated
Figure 7 Effects of berberine and its derivatives on gene expression of inflammatory mediators in atherosclerotic plaques. ApoE−/−
mice were fed with the Western diet for 16 weeks and then treated with BBR or its derivatives (dhBBR and Di-MeBBR) for 16 weeks. Real-time
PCR was performed to determined mRNA expression of CD68 (A), EMMPRIN (B), NFkB p65 (C), MMP-9 (D), ICAM-1 (E), VCAM-1 (F) in the aorta.
*P < 0.05 vs. the control group.
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mice. Di-MeBBR also inhibited MMP-9 expression in
atherosclerotic plaques. Take together, BBR derivatives re-
duce plaque size and improve plaque stability through sup-
pressing both the accumulation of macrophages and the
production of EMMPRIN and MMP-9 by macrophages.
The protective roles of BBR derivatives against athero-
sclerosis are likely mediated by NFκB and MAPK signal-
ing pathways. NFκB pathway is a major transcription
factor that regulates gene expression of a wide variety of
inflammatory mediators including cell adhesion mole-
cules, chemokines, cytokines, and MMPs [30], which are
key players in the pathogenesis and development of ath-
erosclerosis and its complications. There are a variety of
stimuli which can activate NFκB including vascular in-
jury, oxLDL, and cytokines etc. [30]. One of the key
steps in activating NFκB pathway is the stimulation of
the IκB kinases [31]. In unstimulated cells, NFκB canon-
ical signaling pathway p65 is localized predominantly in
the cytoplasm and remains inactivated through binding
with its inhibitory protein, IkB-α. Upon oxLDL stimula-
tion, IκB-α is phosphorylated and subsequently degraded,
which allows p65 to be liberated from IkB-α. NFκB is then
translocated into the nucleus where it binds to a specific
sequence in the promoter of target genes, resulting in in-
creased expression of target genes [30]. NFκB may also be
activated by MAPK signaling pathways [32]. MAPK sig-
naling pathways are known to play an important role inthe pathogenesis of cardiac and vascular disease including
atherosclerosis [33]. Studies have shown that activation of
JNK and p38, but not ERK1/2, is required for foam cell
formation [24,34,35]. Activation of JNK and p38 also in-
duces gene expression of inflammatory mediators such as
adhesion molecules and MMPs [36-38]. Our previous
study found that BBR inhibited activation of NFκB and
p38 induced by oxLDL in macrophages [12,13]. The
current study further demonstrated that dhBBR and Di-
MeBBR exhibited greater inhibition on activation of NFκB
and MAPK (p38 and JNK) in oxLDL-stimulated macro-
phages and on expression of NFκB p65 in atherosclerotic
plaques in apoE−/− mice. BBR derivatives thus exert anti-
inflammatory and anti-atherosclerotic effects by targeting
NFκB and MAPK (p38 and JNK) signaling pathways.
Superiority of BBR derivatives over BBR is likely due to
their enhanced bioavailability. The structure of BBR is ex-
tremely flat, which limits its absorption across the intes-
tinal epithelia. In BBR derivatives, the D ring side chain is
filled with various substituents, alternating the double
bond of ring C and attaching different substituents at the
13-position and other positions [16]. Changing to dhBBR
opens up the structure, making it more amenable to up-
take, which is substantiated by pharmokinetic data [15]. En-
hanced bioavailability of dhBBR leads to improved in vivo
efficacy on metabolism [15]. Once absorbed, dhBBR is rap-
idly converted to BBR, so dhBBR is likely the active moiety.
However, dhBBR can also be converted to BBR in the
Figure 8 Effects of berberine and its derivatives on α-SMA and collagen content and fibrous cap thickness in atherosclerotic plaques.
ApoE−/− mice were fed with the Western diet for 16 weeks and then treated with BBR (B) or its derivatives, Di-MeBBR (C) and dhBBR (D) for
16 weeks. Mice receiving PBS served as the control group (A). Mouse aorta sections were collected. Immunohistochemistry and Masson’s
trichrome staining were performed to determined the positive area of α-SMA,scale bar represents 100 μm (A) and collagen,scale bar represents
500 μm (B) content, respectively. The mean fibrous cap thickness was measured (C). *P < 0.05 vs. the control group.
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duce its bioavailability [15]. Blocking aromatization of
dhBBR 8,8-disubstitution with an alkyl group optimizes
dhBBR into more aqueous soluble and acid stable 8,8-dia-
lkyldihydroberberine hydrochlorides. 8,8-Dimethyl-13,13a-
dihydroberberine (Di-MeBBR) has been identified as a
promising derivative. With improved aqueous solubility
and acid stability, Di-MeBBR has significantly higher bio-
availability without conversion back to BBR in vivo. Di-
MeBBR improves glucose and lipid metabolism in diet-
induced obese mice at a relatively low dosage and has been
shown to be more effective than dhBBR in db/db mice [16].
In the present study, overall, BBR derivatives have better
anti-inflammatory effects than BBR, and reduce athero-
sclerotic plaque size and instability in apoE−/− mice. There
are some differences between Di-MeBBR and dhBBR in
terms of improving plaque stability. Compared to vehicle
control group, Di-MeBBR group has higher collagen con-
tent, whereas dhBBR group has higher α-SMA content and
thicker fibrous cap. We have shown that Di-MeBBR, but
not dhBBR or BBR, significantly reduces MMP-9 gene and
protein expression in apoE−/− mice, which could lead
to reduced collagen degradation and higher collagen
content in Di-MeBBR group. α-SMA is primarily pro-
duced by smooth muscle cells. Whether dhBBR has the
effect on smooth muscle cells needs further investiga-
tion. In addition, in previous studies [12,13] and this
study, we pretreated cells with BBR and its derivatives
before oxLDL stimulation. Our next study will investi-
gate whether treatment of BBR and its derivatives at
the same time of or after oxLDL stimulation will exert
similar anti-inflammatory effects.
Conclusions
Our results demonstrate that BBR derivatives (dhBBR
and Di-MeBBR) have better inflammatory and anti-
atherosclerotic effects compared with BBR. So, BBR de-
rivatives could have therapeutic advantages over BBR as
an adjunct therapy in patients with atherosclerosis.
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